ID
31380
Beschrijving
Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin
Trefwoorden
Versies (2)
- 31-07-18 31-07-18 -
- 18-08-18 18-08-18 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
18 augustus 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593
Notification of Patient Death
- StudyEvent: ODM
Similar models
Notification of Patient Death
- StudyEvent: ODM
C0205394 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0009566 (UMLS CUI [1,3])
C0869014 (UMLS CUI [1,4])
C0011065 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
C0683836 (UMLS CUI [1,2])
C0683836 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C2348235 (UMLS CUI [1,4])